Winslow Evans Crocker buys $8,735,081 stake in Edwards Lifesciences Corp (EW)

Edwards Lifesciences Corp (EW) : Winslow Evans Crocker scooped up 3,800 additional shares in Edwards Lifesciences Corp during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 20, 2016. The investment management firm now holds a total of 80,634 shares of Edwards Lifesciences Corp which is valued at $8,735,081.Edwards Lifesciences Corp makes up approximately 2.58% of Winslow Evans Crocker’s portfolio.

Edwards Lifesciences Corp opened for trading at $107.99 and hit $109.32 on the upside on Friday, eventually ending the session at $108.33, with a gain of 0.21% or 0.23 points. The heightened volatility saw the trading volume jump to 9,20,923 shares. Company has a market cap of $23,247 M.

Other Hedge Funds, Including , Cohen Lawrence B reduced its stake in EW by selling 960 shares or 1.05% in the most recent quarter. The Hedge Fund company now holds 90,336 shares of EW which is valued at $9,786,099. Edwards Lifesciences Corp makes up approx 6.26% of Cohen Lawrence B’s portfolio.Gateway Investment Advisers reduced its stake in EW by selling 7,473 shares or 31.66% in the most recent quarter. The Hedge Fund company now holds 16,128 shares of EW which is valued at $1,747,146. Edwards Lifesciences Corp makes up approx 0.01% of Gateway Investment Advisers’s portfolio.Eqis Capital Management reduced its stake in EW by selling 1,184 shares or 6.73% in the most recent quarter. The Hedge Fund company now holds 16,397 shares of EW which is valued at $1,737,918. Edwards Lifesciences Corp makes up approx 0.12% of Eqis Capital Management’s portfolio.

On the company’s financial health, Edwards Lifesciences Corp reported $0.71 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.66. The company had revenue of $697.30 million for the quarter, compared to analysts expectations of $666.93 million. The company’s revenue was up 18.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.12 EPS.

Many Wall Street Analysts have commented on Edwards Lifesciences Corp. Company shares were Reiterated by Leerink Partners on Apr 4, 2016 to “Outperform”, Firm has raised the Price Target to $ 115 from a previous price target of $93 .Company shares were Reiterated by Canaccord Genuity on Apr 4, 2016 to “Buy”, Firm has raised the Price Target to $ 113 from a previous price target of $95 .Company shares were Reiterated by RBC Capital Mkts on Apr 4, 2016 to “Outperform”, Firm has raised the Price Target to $ 110 from a previous price target of $100 .

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. Patients in the hospital setting including high-risk patients in the operating room or intensive care unit are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Company’s products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy Surgical Heart Valve Therapy and Critical Care.

Leave a Reply

Edwards Lifesciences Corp - Is it time to Sell?

Top Brokerage Firms are advising their investors on Edwards Lifesciences Corp. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.